Imugene share price surges 8% on 'crucial step forward' in US

Imugene is working on products intended to selectively kill tumour cells and activate the immune system against cancer cells.

| More on:
Group of Imugene scientists cheering in the lab after the company received another patent for HER-Vaxx

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Imugene Ltd (ASX: IMU) share price is leaping higher today, up 7.5% at the time of writing.

Shares in the S&P/ASX 200 Index (ASX: XJO) biotechnology company closed yesterday trading for 9.3 cents. Shares are currently swapping hands for 10 cents apiece.

Created with Highcharts 11.4.3Imugene PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

Here's why ASX 200 investors are hitting the buy button today.

What did the ASX 200 biotech stock report?

The Imugene share price is racing higher after the company reported it had received a core patent from the United States Patent and Trademark Office.

The patent protects its oncolytic virotherapy CF33 products, including VAXINIA and CHECKVacc.

Imugene said both the method of composition and method of use of its licensed oncolytic virotherapy will be protected under the US patent until 2037.

According to the release, CF33 is a chimeric vaccinia poxvirus from the lab of inventor professor Yuman Fong. Oncolytic viruses are designed to selectively kill tumour cells and activate the immune system against cancer cells, with the potential to improve clinical response and survival.

Commenting on the patent grant sending the Imugene share price sharply higher today, CEO Leslie Chong said, "Imugene receiving this patent allowance for the CF33 family of oncolytic viruses from the US patent office is a crucial step forward."

She noted that the US is the biggest healthcare market on Earth, making "this is a particularly important patent milestone".

Imugene share price snapshot

Despite today's big intraday lift, the Imugene share price remains down a painful 62% over the past 12 months.

Investors who bought shares five years ago, however, will be sitting on gains of 400%.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »

three excited doctors with hands in the air
Healthcare Shares

Two ASX healthcare shares that could be set to double

This broker has buy recommendations on these two shares. 

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Telix shares jump 7% on big US news

Let's see what is getting investors excited on Wednesday.

Read more »

An older gentleman leans over his partner's shoulder as she looks at a tablet device while seated at a table.
Healthcare Shares

Macquarie tips 28% upside for this ASX healthcare stock

The broker expects big things from this New Zealand retirement village developer and operator.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

$10,000 invested in these ASX healthcare shares 5 years ago is now worth…

These healthcare stocks have brought big returns for investors 

Read more »

A man wearing a white coat and glasses is wide-mouthed in surprise.
Healthcare Shares

Guess which ASX 300 stock is crashing 55% today

What's going on with this stock? Let's see why investors are hitting the sell button.

Read more »

Woman serving customer in pharmacy.
Healthcare Shares

Up 132% in a year, are Sigma Healthcare shares still a good buy post the Chemist Warehouse merger?

After gaining 132% in 12 months, it too late to buy Sigma Healthcare shares today?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Share Market News

Is it too late to buy Pro Medicus shares?

Pro Medicus shares have risen 550% over 3 years. Have you missed the boat? Three experts weigh in.

Read more »